Active clinical trials for "Carcinoma, Small Cell"

The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.

Small cell lung cancer (SCLC) harbors a high risk for brain metastases. Prophylactic whole brain radiotherapy (PCI)) is the standard treatment for these patients after completing chemo-radiotherapy to the chest, with a 5% survival advantage. Recent data suggest minimal risk for hippocampal involvement in these patients. There is no published data thus far testing the effect of hippocampal sparing during WBRT on the patient's neuro-cognitive function, QOL, and survival.., The goals of the proposed study are to assess prospectively the neurocognitive changes in patients with LD SCLC who are candidates for PCI before, and periodically after PCI

As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.

Background: The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer. To establish a repository of genetic information for future studies of these differences and their relation to lung cancer. Eligibility: Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute. Design: After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential. Approximately half a tablespoon of blood will be drawn. Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

This clinical trial studies glycoprotein and glycan in tissue and blood samples of patients with stage IB-IVA cervical cancer undergoing surgery to remove pelvic and abdominal lymph nodes. Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. It may also help doctors learn how far the disease has spread.

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the utility of molecular diagnostic assays for the early detection of lung cancer.

The purpose of this study is to learn more about the metabolic properties of lung cancer cells.

The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.